Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7862250 | 0.97 | FFAR3 (0.47) | FFAR3LCKFYNKDM4ECA2 | |
| Bicarbonate SCHEMBL28549988 | 0.89 | TSHR (0.41) | FFAR3LCKFYNKDM4ECA2 | |
| Acetic Acid SCHEMBL27458299 | 0.83 | FFAR3 (0.47) | FFAR3LCKFYNKDM4ECA2 | |
| SCHEMBL189693 | 0.80 | — | — | |
| Acetic Acid SCHEMBL3143927 | 0.79 | FFAR3 (0.50) | FFAR3LCKFYNKDM4ECA2 | |
| SCHEMBL8074138 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL283187 | 0.76 | — | — | |
| Acetic Acid SCHEMBL7438398 | 0.76 | FFAR3 (0.47) | FFAR3LCKFYNKDM4ECA2 | |
| Hydrochloric Acid SCHEMBL23531965 | 0.72 | — | — | |
| Hydroxyamine SCHEMBL8015019 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450388-B | Composition for removing etching residues, and use method and application thereof | 弗萨姆材料美国有限责任公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119431987-A | High-strength light diffusion backboard and preparation method thereof | 常州丰盛光电科技股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-20240398714-A1 | STABLE CAPSULES WITH FECAL MICROBIOTA OR A CULTURE OF MICROORGANISMS | Chr. Hansen A/S/ (DK) | 2024-12-05 | — | — | US | claimed |
| CN-116492461-A | Palmitoylation inhibitors and PARP inhibitors for use in the treatment of tumors | 大连医科大学附属第二医院 | 2023-07-28 | — | — | CN | claimed |
| US-20230024103-A1 | REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING VIABILITY AND FUNCTION OF CELLS, TISSUES AND ORGANS | TARGA BIOMEDICAL (CA) | 2023-01-26 | — | — | US | claimed |
| US-20220380705-A1 | Composition For Removing Etch Residues, Methods Of Using And Use Thereof | VERSUM MATERIALS US, LLC (US) | 2022-12-01 | — | — | US | claimed |
| CN-115317473-A | Application of palmitoylation inhibitor in preparation of peripheral blood hematopoietic stem/progenitor cell mobilization medicine | 中国人民解放军军事科学院军事医学研究院 | 2022-11-11 | — | — | CN | claimed |
| US-11446265-B2 | Reagents, compositions and methods for improving viability and function of cells, tissues and organs | TARGA BIOMEDICAL (CA) | 2022-09-20 | — | — | US | claimed |
| EP-4034629-A1 | COMPOSITIONS FOR REMOVING ETCH RESIDUES, METHODS OF USING AND USE THEREOF | Versum Materials US, LLC (US) | 2022-08-03 | — | — | EP | claimed |
| CN-114450388-A | Composition for removing etching residues, and use method and application thereof | 弗萨姆材料美国有限责任公司 | 2022-05-06 | — | — | CN | claimed |
| WO-2021061922-A1 | COMPOSITIONS FOR REMOVING ETCH RESIDUES, METHODS OF USING AND USE THEREOF | VERSUM MATERIALS US, LLC (US) | 2021-04-01 | — | — | WO | claimed |
| EP-1265856-B1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | claimed |
| US-6512143-B1 | Salt formation by reaction of alkanoic acid with N-tert-butylhydroxylamine | ASTRAZENECA AB (CH) | 2003-01-28 | — | — | US | claimed |
| EP-1265856-A1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | claimed |
| US-6479697-B2 | BY THE REACTION OF THE CORRESPONDING DISULFOPHENYL ALDEHYDE WITH N-TERT-BUTYLHYDROXYLAMMONIUM ACETATE | ASTRAZENECA AB (SE) | 2002-11-12 | — | — | US | claimed |
| US-20020128318-A1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BURTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | US | claimed |
| WO-2001051460-A1 | NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | claimed |
| EP-1095012-A1 | NOVEL SALTS OF N-TERT-BUTYLHYDROXYLAMINE | AstraZeneca AB (SE) | 2001-05-02 | — | — | EP | claimed |
| WO-2000002848-A1 | NOVEL SALTS OF N-TERT-BUTYLHYDROXYLAMINE | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | claimed |
| EP-3606503-B1 | COMPOSITIONS, KITS AND METHODS FOR COLORING FIBERS | HENKEL AG & CO KGAA (DE) | 2025-10-22 | — | — | EP | disclosed |
| CN-115735000-B | Method for separating lipids from lipid-containing biomass | 赢创运营有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-3682692-B1 | METHOD AND CONTROL UNIT FOR EXCHANGING BACKHAUL INFORMATION BETWEEN RADIO NODES | HUAWEI TECH CO LTD (CN) | 2025-05-21 | — | — | EP | disclosed |
| US-12298669-B2 | Composition comprising three alkanolamines and a hydroxylamine for removing etch residues | VERSUM MATERIALS US, LLC (US) | 2025-05-13 | — | — | US | disclosed |
| EP-3200604-B2 | METHOD FOR PREPARING AN ANIMAL FEED | EVONIK OPERATIONS GMBH (DE) | 2025-05-07 | — | — | EP | disclosed |
| CN-114450388-B | Composition for removing etching residues, and use method and application thereof | 弗萨姆材料美国有限责任公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119431987-A | High-strength light diffusion backboard and preparation method thereof | 常州丰盛光电科技股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240398714-A1 | STABLE CAPSULES WITH FECAL MICROBIOTA OR A CULTURE OF MICROORGANISMS | Chr. Hansen A/S/ (DK) | 2024-12-05 | — | — | US | disclosed |
| EP-4464307-A1 | COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME | MPLUS COSMETICS S.R.L. (IT) | 2024-11-20 | — | — | EP | disclosed |
| US-20240374498-A1 | COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME | MPLUS COSMETICS S.R.L. (IT) | 2024-11-14 | — | — | US | disclosed |
| CN-112166176-B | Method for separating lipids from lipid-containing biomass by means of hydrophobic silica | 赢创运营有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11976253-B2 | Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion | EVONIK OPERATIONS GMBH (DE) | 2024-05-07 | — | — | US | disclosed |
| US-11946017-B2 | Method of separating lipids from a lysed lipids containing biomass | EVONIK OPERATIONS GMBH (DE) | 2024-04-02 | — | — | US | disclosed |
| US-11814665-B2 | Enhanced production of lipids by limitation of at least two limiting nutrient sources | EVONIK OPERATIONS GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| CN-115317473-B | Use of palmitoylation inhibitor in preparation of peripheral blood hematopoietic stem/progenitor cell mobilizing medicine | 中国人民解放军军事科学院军事医学研究院 | 2023-10-13 | — | — | CN | disclosed |
| US-20230242836-A1 | METHOD OF ISOLATING LIPIDS FROM A LIPIDS CONTAINING BIOMASS | DSM IP ASSETS B.V. (NL) | 2023-08-03 | — | — | US | disclosed |
| CN-116492461-A | Palmitoylation inhibitors and PARP inhibitors for use in the treatment of tumors | 大连医科大学附属第二医院 | 2023-07-28 | — | — | CN | disclosed |
| US-11692428-B2 | Downhole dynamometer | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| EP-4168520-A1 | METHOD OF ISOLATING LIPIDS FROM A LIPIDS CONTAINING BIOMASS | Evonik Operations GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| CN-110621296-B | Compositions, kits and methods for coloring fibers | 汉高股份有限及两合公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115735000-A | Method for separating lipids from lipid-containing biomass | 赢创运营有限公司 | 2023-03-03 | — | — | CN | disclosed |
| US-11542220-B2 | Method of isolating lipids from a lipids containing biomass | EVONIK OPERATIONS GMBH (DE) | 2023-01-03 | — | — | US | disclosed |
| US-20220380705-A1 | Composition For Removing Etch Residues, Methods Of Using And Use Thereof | VERSUM MATERIALS US, LLC (US) | 2022-12-01 | — | — | US | disclosed |
| CN-115317473-A | Application of palmitoylation inhibitor in preparation of peripheral blood hematopoietic stem/progenitor cell mobilization medicine | 中国人民解放军军事科学院军事医学研究院 | 2022-11-11 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11464244-B2 | Feedstuff of high abrasion resistance and good stability in water, containing PUFAs | EVONIK OPERATIONS GMBH (DE) | 2022-10-11 | — | — | US | disclosed |
| US-11414621-B2 | Method of isolating lipids from a lipids containing biomass with aid of hydrophobic silica | EVONIK OPERATIONS GMBH (DE) | 2022-08-16 | — | — | US | disclosed |
| EP-4034629-A1 | COMPOSITIONS FOR REMOVING ETCH RESIDUES, METHODS OF USING AND USE THEREOF | Versum Materials US, LLC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11352651-B2 | Method of isolating lipids from a lipids containing biomass | EVONIK OPERATIONS GMBH (DE) | 2022-06-07 | — | — | US | disclosed |
| US-11324234-B2 | Method for raising animals | EVONIK OPERATIONS GMBH (DE) | 2022-05-10 | — | — | US | disclosed |
| CN-114450388-A | Composition for removing etching residues, and use method and application thereof | 弗萨姆材料美国有限责任公司 | 2022-05-06 | — | — | CN | disclosed |
| US-11261400-B2 | Method of separating lipids from a lysed lipids containing biomass | EVONIK OPERATIONS GMBH (DE) | 2022-03-01 | — | — | US | disclosed |
| WO-2021061922-A1 | COMPOSITIONS FOR REMOVING ETCH RESIDUES, METHODS OF USING AND USE THEREOF | VERSUM MATERIALS US, LLC (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-2376462-B1 | THIAZOLES AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-8895592-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8338467-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058293-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2376462-A1 | Thiazoles as cannabinoid receptor ligands | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2334646-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100216760-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2010-07-01 | — | — | US | disclosed |
| WO-2010071783-A1 | THIAZOLES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010033543-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | WEINER, CARL P | 2009-12-24 | — | — | US | disclosed |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-10-01 | — | — | US | disclosed |
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1343752-B1 | METHOD FOR PRODUCING N-SUBSTITUTED HYDROXYLAMINES AND THE SALTS THEREOF | SALTIGO GMBH (DE) | 2007-05-02 | — | — | EP | disclosed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060167223-A1 | Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use | TS PHARMA (FR) | 2006-07-27 | — | — | US | disclosed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
| CN-1198798-C | Novel process for preparation of alpha-(2.4-disulfophenyl)-N-tert-butylnitrone and pharmaceutically acceptable salts thereof | ASTRAZENECA AB (SE) | 2005-04-27 | — | — | CN | disclosed |
| EP-1265856-B1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1265856-B1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1343752-A2 | METHOD FOR PRODUCING N-SUBSTITUTED HYDROXYLAMINES AND THE SALTS THEREOF | Bayer Aktiengesellschaft (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-6559340-B2 | Acidically hydrolyzing aryl- or heteroaryloxaziridine compound using acid and a water-miscible solvent, isolating N-substituted hydroxylamines in the form of their salts | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-06 | — | — | US | disclosed |
| CN-1395559-A | Process for the preparation of alpha- (2, 4-disulfophenyl) -N-tert-butylnitrone and pharmaceutically acceptable salts thereof | ASTRAZENECA AB (SE) | 2003-02-05 | — | — | CN | disclosed |
| US-6512143-B1 | Salt formation by reaction of alkanoic acid with N-tert-butylhydroxylamine | ASTRAZENECA AB (CH) | 2003-01-28 | — | — | US | disclosed |
| EP-1265856-A1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| EP-1265856-A1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| US-6479697-B2 | BY THE REACTION OF THE CORRESPONDING DISULFOPHENYL ALDEHYDE WITH N-TERT-BUTYLHYDROXYLAMMONIUM ACETATE | ASTRAZENECA AB (SE) | 2002-11-12 | — | — | US | disclosed |
| US-6479697-B2 | BY THE REACTION OF THE CORRESPONDING DISULFOPHENYL ALDEHYDE WITH N-TERT-BUTYLHYDROXYLAMMONIUM ACETATE | ASTRAZENECA AB (SE) | 2002-11-12 | — | — | US | disclosed |
| US-20020128318-A1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BURTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | US | disclosed |
| US-20020128318-A1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BURTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | US | disclosed |
| US-20020082453-A1 | Process for preparing N-substituted hydroxylamines and salts thereof | LANXESS DEUTSCHLAND GMBH (DE) | 2002-06-27 | — | — | US | disclosed |
| WO-2002048093-A2 | METHOD FOR PRODUCING N-SUBSTITUTED HYDROXYLAMINES AND THE SALTS THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | WO | disclosed |
| WO-2001051460-A1 | NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051460-A1 | NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | disclosed |
| EP-1095012-A1 | NOVEL SALTS OF N-TERT-BUTYLHYDROXYLAMINE | AstraZeneca AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002848-A1 | NOVEL SALTS OF N-TERT-BUTYLHYDROXYLAMINE | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
| WO-2000002848-A1 | NOVEL SALTS OF N-TERT-BUTYLHYDROXYLAMINE | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | FFAR3 122/4885LCK 2064/4885FYN 1581/4885 |
| US-20020082453-A1 | Process for preparing N-substituted hydroxylamines and salts thereof | HAAO, HNMT, PAH | FFAR3 3507/4885LCK 3244/4885FYN 1090/4885 |
| US-20230024103-A1 | REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING VIABILITY AND FUNCTION OF CELLS, TISSUES AND ORGANS | NFE2L2, HSF1, HSPA9 | FFAR3 3929/4885LCK 2885/4885FYN 2614/4885 |
| US-20060167223-A1 | Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use | ATF1, TLR3, AMPD3 | FFAR3 1879/4885LCK 3184/4885FYN 3595/4885 |
| US-20100216760-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | FFAR3 131/4885LCK 1742/4885FYN 1585/4885 |
| US-20020128318-A1 | NOVEL PROCESS FOR THE PREPARATION OF ALPHA-(2-4-DISULFOPHENYL)-N-TERT-BURTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TERT, SBDS, TTR | FFAR3 2257/4885LCK 1428/4885FYN 742/4885 |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | FFAR3 122/4885LCK 2064/4885FYN 1581/4885 |
| US-11446265-B2 | Reagents, compositions and methods for improving viability and function of cells, tissues and organs | NFE2L2, HSF1, HSPA9 | FFAR3 3929/4885LCK 2885/4885FYN 2614/4885 |
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | FFAR3 76/4885LCK 1751/4885FYN 1325/4885 |
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | FFAR3 313/4885LCK 1210/4885FYN 809/4885 |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | FFAR3 76/4885LCK 1751/4885FYN 1325/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | FFAR3 313/4885LCK 1210/4885FYN 809/4885 |
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | GPX1, SOD1, GPX4 | FFAR3 825/4885LCK 3543/4885FYN 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.